Open AccessPathological findings in central nervous system demyelination associated with infliximab
Author(s) -
Alicja Kalinowska,
Mahboobeh Fereidan-Esfahani,
Yong Guo,
Claudia F. Lucchinetti,
W. Oliver Tobin
Publication year - 2019
Publication title -
multiple sclerosis journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.729
H-Index - 131
eISSN - 1477-0970
pISSN - 1352-4585
DOI - 10.1177/1352458519894710
Subject(s) - infliximab , medicine , multiple sclerosis , central nervous system , rheumatoid arthritis , pathological , demyelinating disorder , tumor necrosis factor alpha , immune system , pathology , immunology
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom